Quest Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Quest Laboratories Ltd is ₹ 137.05 as of 05 May 15:30 . The P/E Ratio of Quest Laboratories Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Quest Laboratories Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Quest Laboratories Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Quest Laboratories Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Quest Laboratories Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Quest Laboratories Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Quest Laboratories Ltd

Quest Laboratories Limited was originally incorporated as 'Quest Laboratories Private Limited' vide Certificate of Incorporation dated June 01, 1998, with the Registrar of Companies, Gwalior.
Thereafter, the status of the Company changed to Public Limited and the name of Company was changed to 'Quest Laboratories Limited' vide fresh Certificate of Incorporation issued on January 23, 2024, by Centralised Processing Centre. The Company is engaged in manufacturing of pharmaceutical formulations including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more.
It produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC).
The Company is an ISO 9001:2015 in accordance with the requirements Quality Management System standard.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Quest Laboratories Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Quest Laboratories Ltd or Sanofi India Ltd?

Market cap of Quest Laboratories Ltd is 236 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Quest Laboratories Ltd and Sanofi India Ltd?

The stock performance of Quest Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Quest Laboratories Ltd and Sanofi India Ltd?

As of May 5, 2026, the Quest Laboratories Ltd stock price is INR ₹144.1. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Quest Laboratories Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Quest Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.